ダウンロード数: 172
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
journal.pone.0058380.pdf | 286.62 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Ueda, Yoshihide | en |
dc.contributor.author | Kaido, Toshimi | en |
dc.contributor.author | Ogura, Yasuhiro | en |
dc.contributor.author | Ogawa, Kohei | en |
dc.contributor.author | Yoshizawa, Atsushi | en |
dc.contributor.author | Hata, Koichiro | en |
dc.contributor.author | Fujimoto, Yasuhiro | en |
dc.contributor.author | Miyagawa-Hayashino, Aya | en |
dc.contributor.author | Haga, Hironori | en |
dc.contributor.author | Marusawa, Hiroyuki | en |
dc.contributor.author | Teramukai, Satoshi | en |
dc.contributor.author | Uemoto, Shinji | en |
dc.contributor.author | Chiba, Tsutomu | en |
dc.contributor.alternative | 上田, 佳秀 | ja |
dc.date.accessioned | 2013-04-30T01:42:59Z | - |
dc.date.available | 2013-04-30T01:42:59Z | - |
dc.date.issued | 2013-03-07 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2433/173624 | - |
dc.description.abstract | [Background]Given the limited efficacy and high adverse event rate associated with treatment of recurrent hepatitis C after liver transplantation, an individualized treatment strategy should be considered. The aim of this study was to identify predictors of response to antiviral therapy for hepatitis C after living donor liver transplantation (LDLT) and to study the associated adverse events. [Methods]A retrospective chart review was performed on 125 hepatitis C virus (HCV)-positive LDLT recipients who received interferon plus ribavirin and/or peginterferon plus ribavirin therapy at Kyoto University between January 2001 and June 2011. [Results]Serum HCV RNA reached undetectable levels within 48 weeks in 77 (62%) of 125 patients, and these patients were defined as showing virological response (VR). Of 117 patients, 50 (43%) achieved sustained VR (SVR). Predictive factors associated with both VR and SVR by univariate analysis included low pretransplant serum HCV RNA levels, a non-1 HCV genotype, and low pretreatment serum HCV RNA levels. In addition, LDLT from ABO-mismatched donors was significantly associated with VR, and white cell and neutrophil counts before interferon therapy were associated with SVR. Multivariate analysis showed that 2 variables–pretransplant serum HCV RNA level less than 500 kIU/mL and a non-1 HCV genotype–remained in models of both VR and SVR and that an ABO mismatch was associated with VR. No variables with a significant effect on treatment withdrawal were found. [Conclusions]Virological response to antiviral therapy in patients with hepatitis C recurring after LDLT can be predicted prior to transplant, based on pretransplant serum HCV-RNA levels and HCV genotype. LDLT from ABO-mismatched donors may contribute to more efficacious interferon therapy. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.rights | © 2013 Ueda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en |
dc.title | Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | PloS one | en |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 3 | - |
dc.relation.doi | 10.1371/journal.pone.0058380 | - |
dc.textversion | publisher | - |
dc.identifier.artnum | e58380 | - |
dc.identifier.pmid | 23505497 | - |
dcterms.accessRights | open access | - |
出現コレクション: | 学術雑誌掲載論文等 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。